Hyperglycemia in animals can be induced by different methods: namely, chemical treatment (eg. streptozotocin, alloxan), dietary intervention (eg. excess feeding of sucrose/fructose/fat) with/without chemical treatment, pancreas removal (pancreatectomy), and genetic modifications (eg. transgenic animals). The current study test if a two-week sequence of oral and intraperitoneal glucose loading can sustain hyperglycemia inSprague Dawley rat.A dose of 80 gm.kg-1BW (feed), 2 gm.kg-1BW.ml-1 (drinking water), 2.25 gm.kg-1BW.ml-1(IP) (first week) and increased in the second week to 80 gm.kg-1BW, 2.5 gm.kg-1BW.ml-1, 2.75 gm.kg-1BW.ml-1 of glucose in feed, drinking water, and injection (two times/day) respectively, was selected from 15 different administered doses. A first week moderate increase in plamsa glucose was observed followed by a sustained elevation in plasma glucose levels in the second week. Plasma glucose levels increased on average to 265 mg.dl-1 and 371 mg.dl-1 on day 9 and day 12, respectively. Moreover, the observed hyperglycemia was sustained through day 14 of the study. In addition, plasma insulin levels also significantly increased from 8.92 μlU.ml-1 in control to 27.24 μlU.ml-1 in the glucose-treated group. Hyperglycemia and the resulting hyperinsulinemia promoted a significant increase in mean areterial pressure (MAP) throughout the entire study.The stated dose is effective to develop a lean hypertensive hyperglycemic Sprague Dawley rat model, thereby excluding the confounding factors of obesity and chemical treatements, when studying cardiovascular, renal, and diabetic complications.